265 related articles for article (PubMed ID: 21595825)
1. Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma.
Shankavaram UT; Bredel M; Burgan WE; Carter D; Tofilon P; Camphausen K
J Cell Mol Med; 2012 Mar; 16(3):545-54. PubMed ID: 21595825
[TBL] [Abstract][Full Text] [Related]
2. HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma.
Zhang JX; Han L; Bao ZS; Wang YY; Chen LY; Yan W; Yu SZ; Pu PY; Liu N; You YP; Jiang T; Kang CS;
Neuro Oncol; 2013 Dec; 15(12):1595-603. PubMed ID: 24203894
[TBL] [Abstract][Full Text] [Related]
3. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
4. Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma.
Chen CH; Chen PY; Lin YY; Feng LY; Chen SH; Chen CY; Huang YC; Huang CY; Jung SM; Chen LY; Wei KC
J Neurosurg; 2019 Jan; 132(1):168-179. PubMed ID: 30641835
[TBL] [Abstract][Full Text] [Related]
5. The PDK1/c‑Jun pathway activated by TGF‑β induces EMT and promotes proliferation and invasion in human glioblastoma.
Luo D; Xu X; Li J; Chen C; Chen W; Wang F; Xie Y; Li F
Int J Oncol; 2018 Nov; 53(5):2067-2080. PubMed ID: 30106127
[TBL] [Abstract][Full Text] [Related]
6. TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth.
Di K; Linskey ME; Bota DA
Oncogene; 2013 Oct; 32(42):5038-47. PubMed ID: 23178488
[TBL] [Abstract][Full Text] [Related]
7. Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth.
Lee J; Shin YJ; Lee K; Cho HJ; Sa JK; Lee SY; Kim SH; Lee J; Yoon Y; Nam DH
Cancer Res Treat; 2018 Jul; 50(3):1009-1022. PubMed ID: 29129044
[TBL] [Abstract][Full Text] [Related]
8. MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma.
Bell JB; Eckerdt FD; Alley K; Magnusson LP; Hussain H; Bi Y; Arslan AD; Clymer J; Alvarez AA; Goldman S; Cheng SY; Nakano I; Horbinski C; Davuluri RV; James CD; Platanias LC
Mol Cancer Res; 2016 Oct; 14(10):984-993. PubMed ID: 27364770
[TBL] [Abstract][Full Text] [Related]
9. hHSS1: a novel secreted factor and suppressor of glioma growth located at chromosome 19q13.33.
Junes-Gill KS; Gallaher TK; Gluzman-Poltorak Z; Miller JD; Wheeler CJ; Fan X; Basile LA
J Neurooncol; 2011 Apr; 102(2):197-211. PubMed ID: 20680400
[TBL] [Abstract][Full Text] [Related]
10. Cell line-based xenograft mouse model of paediatric glioma stem cells mirrors the clinical course of the patient.
Larsson S; Wenger A; Dósa S; Sabel M; Kling T; Carén H
Carcinogenesis; 2018 Oct; 39(10):1304-1309. PubMed ID: 29982329
[TBL] [Abstract][Full Text] [Related]
11. miR-663 Suppresses Oncogenic Function of CXCR4 in Glioblastoma.
Shi Y; Chen C; Yu SZ; Liu Q; Rao J; Zhang HR; Xiao HL; Fu TW; Long H; He ZC; Zhou K; Yao XH; Cui YH; Zhang X; Ping YF; Bian XW
Clin Cancer Res; 2015 Sep; 21(17):4004-13. PubMed ID: 26023083
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
[TBL] [Abstract][Full Text] [Related]
13. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA‑422a functions as a tumor suppressor in glioma by regulating the Wnt/β‑catenin signaling pathway via RPN2.
Sun J; Chen Z; Xiong J; Wang Q; Tang F; Zhang X; Mo L; Wang C; Fan W; Wang J
Oncol Rep; 2020 Nov; 44(5):2108-2120. PubMed ID: 33000268
[TBL] [Abstract][Full Text] [Related]
15. Functional genomics analyses of RNA-binding proteins reveal the splicing regulator SNRPB as an oncogenic candidate in glioblastoma.
Correa BR; de Araujo PR; Qiao M; Burns SC; Chen C; Schlegel R; Agarwal S; Galante PA; Penalva LO
Genome Biol; 2016 Jun; 17(1):125. PubMed ID: 27287018
[TBL] [Abstract][Full Text] [Related]
16. Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.
Kratzsch T; Kuhn SA; Joedicke A; Hanisch UK; Vajkoczy P; Hoffmann J; Fichtner I
J Cancer Res Clin Oncol; 2018 May; 144(5):809-819. PubMed ID: 29427211
[TBL] [Abstract][Full Text] [Related]
17. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
18. Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.
Hui AM; Zhang W; Chen W; Xi D; Purow B; Friedman GC; Fine HA
Cancer Res; 2004 Dec; 64(24):9115-23. PubMed ID: 15604281
[TBL] [Abstract][Full Text] [Related]
19. The role of PTRF/Cavin1 as a biomarker in both glioma and serum exosomes.
Huang K; Fang C; Yi K; Liu X; Qi H; Tan Y; Zhou J; Li Y; Liu M; Zhang Y; Yang J; Zhang J; Li M; Kang C
Theranostics; 2018; 8(6):1540-1557. PubMed ID: 29556340
[TBL] [Abstract][Full Text] [Related]
20. Gelsolin knockdown confers radiosensitivity to glioblastoma cells.
Gao D; Jiang T; Liu Y
Cancer Med; 2024 May; 13(10):e7286. PubMed ID: 38803199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
